Relief Therapeutics Holding AG (RLFTY)
USD 3.59
(5.59%)
USD 3.59
(5.59%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -108.03 Million CHF | 32.74% |
| 2022 | -49.02 Million CHF | 26.57% |
| 2021 | -32.69 Million CHF | -60.34% |
| 2020 | -19.36 Million CHF | -2432.41% |
| 2019 | -827 Thousand CHF | -219.31% |
| 2018 | -259 Thousand CHF | 85.69% |
| 2017 | -1.81 Million CHF | 19.38% |
| 2016 | -16.8 Million CHF | -5.13% |
| 2015 | 2.02 Million CHF | 64.54% |
| 2014 | -6.02 Million CHF | 39.28% |
| 2013 | -9.91 Million CHF | -54.77% |
| 2012 | 478.1 Thousand CHF | 88.74% |
| 2011 | -56.87 Million CHF | -269.81% |
| 2010 | -15.38 Million CHF | -87.83% |
| 2009 | -8.18 Million CHF | -64.55% |
| 2008 | -4.97 Million CHF | -319.19% |
| 2007 | 2.27 Million CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.27 Million CHF | 80.89% |
| 2024 Q2 | -1.27 Million CHF | 0.0% |
| 2023 Q4 | -6.64 Million CHF | -91.28% |
| 2023 Q2 | -9.94 Million CHF | -96.64% |
| 2023 Q1 | -5.05 Million CHF | 63.23% |
| 2023 Q3 | -3.47 Million CHF | 65.06% |
| 2023 FY | - CHF | 32.74% |
| 2022 Q3 | -6.54 Million CHF | 65.41% |
| 2022 Q4 | -13.75 Million CHF | -109.99% |
| 2022 FY | - CHF | 26.57% |
| 2022 Q1 | -9.19 Million CHF | -2.46% |
| 2022 Q2 | -18.93 Million CHF | -105.87% |
| 2021 Q3 | -8.42 Million CHF | -2552.11% |
| 2021 Q2 | 343.5 Thousand CHF | 0.0% |
| 2021 FY | - CHF | -60.34% |
| 2021 Q4 | -8.97 Million CHF | -6.58% |
| 2021 Q1 | 343.5 Thousand CHF | 102.18% |
| 2020 Q1 | -1.75 Million CHF | -233.13% |
| 2020 Q3 | -7.92 Million CHF | -126.21% |
| 2020 Q4 | -15.79 Million CHF | -99.19% |
| 2020 FY | - CHF | -2432.41% |
| 2020 Q2 | -3.5 Million CHF | -100.03% |
| 2019 Q4 | -526 Thousand CHF | -100.0% |
| 2019 FY | - CHF | -219.31% |
| 2019 Q2 | -420 Thousand CHF | -100.0% |
| 2019 Q1 | -210 Thousand CHF | -566.67% |
| 2019 Q3 | -263 Thousand CHF | 37.38% |
| 2018 Q4 | -31.5 Thousand CHF | 0.0% |
| 2018 FY | - CHF | 85.69% |
| 2018 Q1 | -210 Thousand CHF | 38.69% |
| 2018 Q2 | -210 Thousand CHF | 0.0% |
| 2018 Q3 | -31.5 Thousand CHF | 85.0% |
| 2017 Q2 | -524 Thousand CHF | 0.0% |
| 2017 Q1 | -524 Thousand CHF | 36.75% |
| 2017 Q3 | -342.5 Thousand CHF | 34.64% |
| 2017 Q4 | -342.5 Thousand CHF | 0.0% |
| 2017 FY | - CHF | 19.38% |
| 2016 Q3 | -826 Thousand CHF | -82500.0% |
| 2016 FY | - CHF | -5.13% |
| 2016 Q1 | -1000.00 CHF | 0.0% |
| 2016 Q2 | -1000.00 CHF | 0.0% |
| 2016 Q4 | -828.5 Thousand CHF | -0.3% |
| 2015 FY | - CHF | 64.54% |
| 2014 FY | - CHF | 39.28% |
| 2013 FY | - CHF | -54.77% |
| 2012 FY | - CHF | 88.74% |
| 2011 FY | - CHF | -269.81% |
| 2010 FY | - CHF | -87.83% |
| 2009 FY | - CHF | -64.55% |
| 2008 FY | - CHF | -319.19% |
| 2007 FY | - CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Qrons Inc. | -40.08 Thousand USD | -269444.173% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 214.885% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 20583.36% |
| Adynxx, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -580.767% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -6073.489% |
| BioStem Technologies, Inc. | -7.55 Million USD | -1330.25% |
| CSL Limited | 4.78 Billion USD | 102.256% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -2681.336% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -521.969% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -95.226% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -11430.617% |
| Skye Bioscience, Inc. | -13.54 Million USD | -697.458% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -29319.886% |
| Rebus Holdings, Inc. | -951 Thousand USD | -11260.252% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -16983.329% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | -52.086% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -1722.19% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -45074.995% |
| SQZ Biotechnologies Company | -64.14 Million USD | -68.435% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -3985.389% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -6933.369% |
| Mesoblast Limited | -62.38 Million USD | -73.163% |
| Marizyme, Inc. | -34.28 Million USD | -215.144% |
| Genus plc | 73.7 Million USD | 246.589% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -1534.058% |
| Pharming Group N.V. | 9.87 Million USD | 1193.814% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -7163.354% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -2945.843% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -1131.601% |
| ContraFect Corporation | -64.99 Million USD | -66.212% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -2286.906% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -7606.904% |
| IMV Inc. | -35.52 Million USD | -204.126% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -4549.069% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -20754.519% |
| ONE Bio Corp. | 13.61 Million USD | 893.621% |
| Accustem Sciences Inc. | -3.74 Million USD | -2783.714% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -124.016% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -8426.026% |
| Q BioMed Inc. | -617.62 Thousand USD | -17392.083% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 3124.524% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -4629.11% |
| Biomind Labs Inc. | -1.03 Million USD | -10342.811% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -172.564% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -3635.264% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -1408.614% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 1606822.189% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -432044.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -4218.051% |
| GB Sciences, Inc. | -1.41 Million USD | -7508.785% |
| Alpha Cognition Inc. | -9.7 Million USD | -1013.13% |
| HST Global, Inc. | -5303.00 USD | -2037161.927% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -5152.115% |
| Halberd Corporation | -74.27 Thousand USD | -145346.223% |
| Enzolytics Inc. | -2.12 Million USD | -4991.165% |
| Agentix Corp. | -1.37 Million USD | -7775.745% |
| Resverlogix Corp. | -11.74 Million USD | -820.082% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -3427.112% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 49.989% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 8977.239% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 1320.222% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -7107.657% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 28617.279% |
| AVAX Technologies, Inc. | -6.11 Million USD | -1667.419% |
| Zenith Capital Corp. | -8.6 Million USD | -1155.357% |
| Genscript Biotech Corporation | -248.71 Million USD | 56.563% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -620048.097% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -4316.012% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -61275.596% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -5524.206% |
| Kadimastem Ltd | -2.62 Million USD | -4016.628% |
| Helix BioMedix, Inc. | -1.04 Million USD | -10225.41% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -59559.392% |
| LadRx Corporation | 412.28 Thousand USD | 26304.331% |
| Cell Source, Inc. | -4.27 Million USD | -2428.621% |
| Regen BioPharma, Inc. | 1.46 Million USD | 7469.662% |
| NovAccess Global Inc. | -1.03 Million USD | -10340.309% |
| Affymax, Inc. | -14.29 Million USD | -655.761% |
| Itoco Inc. | -1.86 Million USD | -5680.433% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -28358.985% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -9580.645% |
| Mobile Lads Corp. | -2.24 Million USD | -4720.542% |
| CytoDyn Inc. | -18.02 Million USD | -499.235% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -136604.248% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -883341.001% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -22144.368% |
| SYBLEU INC | -141.57 Thousand USD | -76212.239% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -10072.786% |
| International Stem Cell Corporation | 202 Thousand USD | 53583.168% |
| Bioxytran, Inc. | -3.82 Million USD | -2728.059% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -205135.562% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -4288.261% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -201.196% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -239980.0% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -3845.8% |
| Neutra Corp. | -181.24 Thousand USD | -59507.056% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -435.919% |
| PureTech Health plc | -11.62 Million USD | -829.182% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -435.956% |
| IXICO plc | -707 Thousand USD | -15180.905% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -1305.804% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -123.464% |
| CSL Limited | 4.73 Billion USD | 102.283% |
| Cellectis S.A. | -92.63 Million USD | -16.624% |